Stem Cell Clinic

Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenstrm Macroglobulinemia – Cancer Therapy Advisor

A case study published in Leukemia and Lymphoma described a patient with a diagnosis of Waldenstrm Macroglobulinemia (WM) that had subsequently undergone histological transformation to refractory high grade B-cell lymphoma and was successfully treated with CD19-targeted chimeric antigen receptor (CAR)-T cell therapy.1

WMis a type of B-cell non-Hodgkin lymphoma(NHL), typically characterized by overproduction of monoclonal immunoglobulinM, as well as infiltration of malignant lymphoplasmacytic cells into the bonemarrow.

Although considered incurable, WM often follows an indolent course andsome patients can be asymptomatic for long periods. Rarely, the diseasetransforms into a more aggressive form of NHL that has been associated with apoor prognosis.

The patient described in the case studywas a 71-year-old man who was first diagnosed with WM in 1998. The patient wasmonitored without undergoing active treatment for a period of 12 years, atwhich time he developed anemia and splenomegaly. At that time, he underwenttreatment with 6 cycles of fludarabine and rituximab and achieved a partial response totreatment. Following a worsening of symptoms 4 years later, the patient wastreated with 6 cycles of bendamustine and rituximab.

Biopsyof an enlarged cervical lymph node performed at that time revealed high-gradeB-cell lymphoma that was clonally related to the previously seenlymphoplasmacytic infiltrate, consistent with transformation.

Thepatient subsequently achieved a complete response to 6 cycles of rituximab,cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) plus ibrutinibfollowed by 6 months of ibrutinib maintenance therapy that lasted for 18months.

Salvagetherapy included 2 cycles of rituximab, dexamethasone, cytarabine, cisplatin(R-DHAP) followed by 1 cycle of rituximab plus high-dose cytarabine, followedby autologous stem cell transplantation several months later.

Asthe patients disease was considered to be chemorefractory based on subsequent imagingand pathological analyses, he was treated with axicabtagene ciloleucel, aCD19-targeted CAR-T cell therapy currently approved for the treatment of adultpatients with relapsed or refractory large B-cell lymphoma, including high gradeB-cell lymphoma, after 2 or more lines of systemic therapy.2

Althoughthe patient experienced pancytopenia, grade 1 cytokine release syndrome, andgrade 1 neurotoxicity following CAR-T therapy, he achieved a complete response1 month following treatment.

Notably,there was no evidence of either underlying WM or transformed disease at 6 and 12months follow-up.

Thestudy authors noted that longer term follow up in this patient will beinformative, as late relapses have occurred even in patients who achieve a deepresponse after transplant. CAR-T cell therapy may be an effective treatment forrelapsed or refractory WM that has not yet undergone histologicaltransformation, as CD19 is almost universally expressed on lymphoplasmacyticlymphoma cells. The researchers concluded that further analysis of this iswarranted in the context of clinical trials.

References

Read more:
Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenstrm Macroglobulinemia - Cancer Therapy Advisor

Equine Medical Research Funding Receives USEA Board of Governors – United States Eventing Association

Oct 15, 2019

The Equine Medical Research Fund was created in 2014 to provide consistent funding for equine medical research, which has historically been underfunded. A $1.00 starter fee was added to each USEA recognized event entry beginning in 2014, and at years end a majority of those dollars were distributed through the Morris Animal Foundation, which assists the USEA with selecting studies to fund, monitoring the funds, and reporting on progress. Morris has decades of experience in reviewing grant applications from universities and research institutions and has a team of veterinarians who spend thousands of volunteer hours assessing which studies are most likely to impact horse welfare. Ultimately, a committee from the USEA comprised of riders and veterinarians will determine which studies the USEA dollars will target.

This years committee recommendation is a bit different as the committee is recommending spreading funds among three entities - the Stephen Teichman Farrier study, a Grayson Jockey Club Research Foundation study, and two Morris Animal Foundation Studies.

Through these partnerships, the USEA is helping to address the major problem of equine research underfunding while maintaining control over how member dollars are distributed. Although the committee is always interested in recommending studies that concern general horse welfare, this year we took a closer look at recommending studies that were geared to solving issues that concern performance horses. The goal of our selection philosophy is to provide USEA positive PR through funding a variety of institutions and studies that show our support for horse care, welfare, and rehabilitation.

In 2017, $46,900 dollars were distributed between five different studies on different topics pertaining to equine health, from improving regenerative therapies to studying gaps in the equine genome related to tendon health.

In 2018, $44,858 dollars were distributed between four different studies on a variety of topics including insulin's relation to laminitis, stem cell therapies, equine asthma, and joint infections.

At the USEA Board of Governors meeting in August, the Equine Medical Research Committee recommended the funding of four studies using the $39,581 collected in 2018 and the Board approved their recommendation. Below are additional details about the four selected studies.

Non-Invasive Evaluation of Host-Microbiota Interactions Canaan Whitfield-Cargile, Texas A&M

Summary: This study aims to develop a non-invasive platform to serve as a diagnostic test for gastrointestinal inflammation prior to severe disease and to reveal how bacteria in the gut influence horse health.

Description: One of the most important and common classes of diseases affecting horses are gastrointestinal (GI) diseases including colic and colitis. Despite tremendous research efforts to both diagnose and prevent these diseases, they remain very common and frequently are not diagnosed until severe disease is present. One area that is gaining recognition as an important player in equine GI health and disease is GI bacteria or the microbiota. The microbiota consists of all of the bacteria and other microorganisms in the GI tract. Alterations in the amounts and types organisms that make up the microbiota have been linked to both GI and non-GI diseases of horses including colic, colitis, laminitis, and obesity. These findings are part of the reason why there are a vast array of prebiotics, probiotics, and other products on the market that claim to influence the GI microbiota. Unfortunately, there is minimal evidence to support the efficacy of these products and a lack of understanding of how these products work. A major contributor to the lack of evidence and understanding of these products is related to an inability to monitor the health and function of the equine GI tract. It is clear when severe disease is present but currently impossible to monitor subtle changes. Similarly, while we can easily diagnose severe inflammation and microbiota changes during disease, we cannot capture the changes that occurred prior to clinical disease. These limitations result in capturing results of GI injury and disease but not causes. Consequently, there is great need for improved understanding of the causes of disease and early identification of horses at-risk of developing GI disease. In the absence of such knowledge, effective intervention strategies to reduce GI and GI-related health risks will remain elusive.

Horses and other animals naturally shed cells lining the GI tract on a daily basis. People, in fact, shed up to 1/3 of the cells lining their GI tract daily. We have developed a technique for examining the gene expression profile of these cells to monitor the health and function of the GI tract from fecal samples. We have shown that this approach offers a promising means to non-invasively examine the response of the GI intestinal tract to injury. Further, we have convincing preliminary data demonstrating that the gene expression profile arising from these cells mirrors the gene expression profile of the tissues within the GI tract of the horse and provides a global view of the health and function of the GI tract. This approach offers a highly attractive, non-invasive means of monitoring GI responsiveness to disease and interventions. Thus, our long-term goals are to 1) develop inexpensive, non-invasive diagnostic tests in order to document GI inflammation prior to the onset of severe disease in horses; and, 2) by examining host and microbiota data simultaneously we aim to elucidate the mechanisms of host-microbiota interactions in the context of health and disease. Ultimately, we aim to use this approach to identify specific pathway by which the host and microbiota interact so that this critically important interaction can be targeted therapeutically.

In order to achieve our goals, we will utilize a reversible model of GI inflammation with which we have extensive experience. We will induce GI inflammation with the non-steroidal anti-inflammatory drug (NSAID) phenylbutazone and noninvasively interrogate the response and response of the microbiota. Importantly, we will collect samples sequentially both before and after induction of inflammation in order to gain predictive and diagnostic information about GI inflammation in horses. This approach will have broad application to many equine intestinal disorders and will provide the much needed mechanistic insight into disease development and progression, thereby enabling us to develop effective prevention and treatment strategies for equine GI disease.

The total cost of this study is $46,756 in 2019 and $45,814 in 2020. The EMRC recommends $12,000 for funding this study.

Paraoxonase-1 Activity as a Marker for Diagnosis of Equine Metabolic Syndrome Gabriele Rossi, DVM, Ph.D., DECVCP Murdoch University

Summary: Researchers will investigate a new laboratory test to improve diagnosis of equine metabolic syndrome, a metabolic and hormonal disorder in horses.

Description: Equine metabolic syndrome (EMS) is characterized by abnormal insulin regulation, obesity, and susceptibility to laminitis. EMS is challenging to diagnose since laboratory tests fail to distinguish EMS from other common equine diseases. Human metabolic syndrome (HMS) shares similar laboratory features to EMS and a new serum biomarker has been proposed in human medicine to improve the diagnosis of HMS. Researchers will investigate if this new HMS test also can provide an accurate diagnosis for horses with EMS. A new efficient and cost-effective EMS test will help veterinarians better diagnose and manage this complex disease in horses.

The total cost of this study is $9,355. The EMRC recommends $9,355 to fund this study.

Cell-mediated immunogenicity and MHC expression regulation of TGF-beta2-treated mesenchymal stem cells for improved clinical use in the horse. Lauren V Schnabel, DVM, Ph.D., DACVS, DACVSMR North Carolina State University

Summary: Researchers will manipulate the expression of immune markers on stem cells to develop safer and more effective therapies for horses with musculoskeletal injuries.

Description: Stem cell therapies have the potential to improve the outcome of potentially severe and life-ending musculoskeletal injuries in horses. However, sometimes the recipients immune system will destroy transplanted stem cells if the immune system perceives the introduced cells as foreign. To improve stem cell treatment success, researchers will examine if a novel cell culture treatment can be used to prevent the immune system from destroying donor stem cells. This study will help researchers better understand the cellular regulation of the molecules that initiate immune responses and advance the development of convenient and effective off-the-shelf stem cell therapy.

The total cost of this study is $131,479. The EMRC recommends $12,000 to fund this study. This is the second year that we are recommending funding this 3 year study.

Stephen Teichman Study

The goal is to determine the effects of front shoe surface modifications in the sport horse on the duration of breakover. We discussed and agreed to support this study during the May BOG conference call providing the publishing and professional fees were researched and found to be reasonable, which they were.

The total cost of this study is $9,640. The EMRC recommends USEA to provide $4,820 and an additional $4,820 is to be contributed by other donors.

This brings the total recommended research total to $38,175, leaving $1,406 of use at another time.

For an update on studies previously selected for funding by the USEA Equine Medical Research Committee, click here. To learn more about how the Equine Medical Research Fund got started, click here. For additional information about the Fund, click here.

View original post here:
Equine Medical Research Funding Receives USEA Board of Governors - United States Eventing Association

Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress – Business Wire

NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (Rocket), a leading U.S.-based multi-platform gene therapy company, today announces data presentations at the upcoming European Society of Cell and Gene Therapy (ESGCT) 27th Annual Congress taking place October 2225, 2019, in Barcelona, Spain. Presentations at this years meeting include four oral presentations and one poster presentation related to Rockets lentiviral pipeline programs for Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD), Pyruvate Kinase Deficiency (PKD), and Infantile Malignant Osteopetrosis (IMO).

Details for Rockets oral and poster presentations are as follows:Title: Towards Haematopoietic Stem Cell-Targeted Gene Therapy of Infantile Malignant OsteopetrosisSession Title: Skeletal Muscle & Bone Gene TherapySession Date: Wednesday, October 23, 2019Session Time: 5:30 PM 7:30 PM CESTRoom: 116-117

Title: Gene Therapy for Patients with Fanconi AnaemiaSession Title: Gene Therapy Clinical Trials IISession Date: Thursday, October 24, 2019Session Time: 8:30 AM - 10:30 AM CESTRoom: 113-117

Title: First Steps of a Lentiviral Gene Therapy Clinical Trial for Pyruvate Kinase DeficiencySession Title: Blood DiseasesSession Date: Thursday, October 24, 2019Session Time: 2:45 PM - 4:45 PM CESTRoom: 211

Title: Broad Applicability of NHEJ-Mediated Gene Editing to Correct Mutations in a Variety of Fanconi Anaemia GenesSession Title: New Approaches in Gene EditingSession Date: Friday, October 25, 2019Session Time: 9:00 AM - 11:00 AM CESTRoom: 113-115

Title: Stable Transduction of Long-Term HSCs Under Optimized GMP-Conditions for the Gene Therapy of LAD-I PatientsSession Title: Poster Session IISession Date: Thursday, October 24, 2019Session Time: 1:15 PM - 2:45 PM CESTPoster Number: P228

Full results from the ESGCT presentations will be available online at the conclusion of the presentation: https://www.rocketpharma.com/esgct-presentations/

About Rocket Pharmaceuticals, Inc.Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rockets multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's first two clinical programs using LVV-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, and Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal. Rockets first clinical program using AAV-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rockets pre-clinical pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD) and Infantile Malignant Osteopetrosis (IMO). For more information about Rocket, please visit http://www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking StatementsVarious statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to successfully demonstrate the efficacy and safety of such products and pre-clinical studies and clinical trials, its gene therapy programs, the pre-clinical and clinical results for its product candidates, which may not support further development and marketing approval, the potential advantages of Rocket's product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's and its licensors ability to obtain, maintain and protect its and their respective intellectual property, the timing, cost or other aspects of a potential commercial launch of Rocket's product candidates, Rocket's ability to manage operating expenses, Rocket's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Annual Report on Form 10-K for the year ended December 31, 2018. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

See the article here:
Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress - Business Wire

ROOT OF SKIN Skincare Products Sell Out in Tenth Consecutive Appearance on QVC Japan – PRNewswire

IRVINE, Calif., Oct. 15, 2019 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that the Company's ROOT of SKIN line of rejuvenating skincare products sold out in its tenth appearance on the Japanese home shopping channel QVC Japan.

ROOT of SKIN is AIVITA's proprietary skincare line for skin rejuvenation, made possible through the same proprietary knowledge and expertise used to develop its cutting-edge stem cell therapies. SourceCode Technology, the proprietary actives complex in ROOT of SKIN, contains the complete set of factors and supporting biological components present in young, healthy skin.

AIVITA Biomedical uses 100% of the proceeds from ROOT of SKIN sales to support the treatment of women with ovarian cancer.

"Outstanding market traction, a product that truly works, and a benevolent use of proceeds," said Hans Keirstead, AIVITA's Chief Executive Officer. "This sets the stage for global expansion of our ROOT of SKIN product line."

About ROOT OF SKIN

ROOT of SKIN is a rejuvenating line of skincare products fueled by an unrelenting pursuit for advancements in life-changing and life-saving treatments. Harnessing breakthroughs in stem cell therapy, AIVITA Biomedical developed a technology that does more than just boost regeneration. The patented actives complex SourceCode Technology renews, repairs and protects, just as your skin did at its youngest and healthiest stage. Rich with every biological component healthy skin needs for development, and free of any unnecessary ingredients. All proceeds support treatment of women with ovarian cancer.

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products.

SOURCE AIVITA Biomedical, Inc.

Read the original post:
ROOT OF SKIN Skincare Products Sell Out in Tenth Consecutive Appearance on QVC Japan - PRNewswire

Joy as funding rises for Moscow treatment trip – Northern Times

A trip to Russia is top of Tain woman Michele Murrays Christmas wish list for 2020.

But the mother-of-two has a more serious reason to visit the country rather than just a holiday trip.

She was diagnosed with multiple sclerosis 15 years and is now desperate to undergo groundbreaking treatment available to her in Russia but which she cannot access in the UK.

Michele (46) launched a 42,000 fundraising drive at the start of September and it is already going well so her hopes of achieving her goal next year are high.

She said: My fundraiser currently stands at 15,000 and I wanted to say a massive thank you to everyone who has donated. The amount given is really staggering.

Michele had to retire from her job as a secretary eight years ago after her condition took a turn for the worse.

At present I use a walking stick, rollator and wheelchair, she said. I have fatigue, muscle spasms, balance problems and weakness in my legs and arms. My MS is getting worse all the time and I feel that if I dont do something now, it will be too late.

It is such an invisible disease. I look fine on the outside, however on the inside my immune system is attacking my central nervous system and causing scarring on my brain/spinal column.

She only recently heard about Hematopoietic Stem Cell Transplant (HSCT), a treatment designed to stop MS in its tracks.

A high dose of chemotherapy is used to kill off my existing failing immune system. she said. My stem cells will then be re-infused to build a brand new immune system free of MS.

The treatment is available in the UK but Michelle does not fit the criteria and to access it privately is costly. However the National Pirogov Medical Centre Russiain Moscow offers HSCT for 42,000.

I hope I will be able to get this life-changing treatment so I can have a better quality of life., said Michelle.

She has been organising various fundraisers and on Saturday, December 28 , RythmnReel will play at the Duthac Centre, Tain, with all proceeds going to help send her to Russia.

To make a donation, visit Go Fund Me and search for Michele Murray.

Read the original post:
Joy as funding rises for Moscow treatment trip - Northern Times

Sarah Ferguson reveals highlight of my life as she celebrates 60th birthday – Express

The Duchess of York, affectionately known by British royal fans as Fergie, shared the cover of The Perfect World Magazine, where she can be seen giving Sir David Attenborough an honorary award. Fergie, who turns 60 today, revealed in an Instagram post that moment is one of the best of her life.

She wrote on Instagram: "Thank you all for the birthday messages! This is one of the highlights of my life."

In the cover, Fergie can be seen smiling as she hands the award, shaped like a rhino, toSir Attenborough, the world-famousEnglish broadcaster and natural historian.

Fergie andSir Attenborough attended together last September thePerfect World Foundation gala dinner, where she will present him the award.

The same award has been previously given toMark Shand, the late brother of the Duchess of Cornwall, and primatologist Dr Jane Goodall.

In the early afternoon, the Duchess of York published on Instagram another picture, showing her wearing a colourful sari.

She added in the caption: "Colourful moments"

Fergie's Instagram messages come after her former husband Prince Andrew celebrated her birthday on social media.

Earlier this morning, the Duke of Yorkpublished two identical messages dedicated to Fergie on both Instagram and Twitter.

READ MORE:How Fergie was 'forced to cancel birthday party due to crisis'

The messages read: "Wishing Sarah Ferguson a very Happy 60th Birthday!"

On Instagram, the message was accompanied by three pictures, one depicting Sarah surrounded by members of the York family, including Princess Eugenie's husband Jack Brooksbank and Princess Beatrice's fiancee Edoardo Mapelli Mozzi.

The second picture shows Fergie surrounded by children supported by the charity she is a patron of, Street Child UK.

And the third snap depicts Eugenie, Beatrice and Fergie together while carrying out an engagement.

DON'T MISS

Fergie has previously spoke with enthusiasm about her approaching 60th birthday.

Speaking at a charity event held onbehalf of Street Child and hosted by Hello, the Duchess said:"I think it's really important that my life is beginning at 60, I'm so excited by it."

Outspoken Fergie also revealed she has undertaken laser treatment to her skin to look her best for her milestone birthday.

Similarly, the Duchess had laser also before the wedding of her youngest daughter Princess Eugenie, which helped to make her skin glow.

But these haven't been the only beauty treatments Fergie has undertaken in the past years.

In March this year, Fergie travelled to the Bahamas toundergo stem cell therapy - an alternative to surgery which is yet to be proven fully safe and effective on humans and is therefore not widely available in the UK.

This therapy helped her solving a painful problem related to her feet, which eventually forced her to stop wearing high heels.

I went to the Bahamas in March to have the treatment.

I think my toes were ruined by all the riding I did when I was young.

Read more here:
Sarah Ferguson reveals highlight of my life as she celebrates 60th birthday - Express

Second annual Regenerative Medicine summit proves big win for The Bahamas – EyeWitness News

Nassau, The Bahamas The best and brightest global recently gathered in The Bahamas to discuss ways of making stem cell and regenerative health technologies available, accessible and affordable to everyone, everywhere.

Dr. Desiree Cox, Rhodes Scholar and Founder and CEO of HEALinc reflects, This event promotes research and innovation in medical technologies with the potential to help people stay healthy through their lifespan. Our presenters and sponsors delivered an immersive experience that bridged the gaps between modern regenerative medicine technologies and ancient healing arts of creativity, music, movement and breathwork.

The second annual HEALinc Future Health and Innovation Summit was hosted at the Grand Hyatt, Baha Mar Convention Center from October 2 4, 2019 with an audience of more than 200-participants. A slate of more than 50 presenters delivered thought-provoking presentations and the celebrity keynote speech was given by Dr. Joe Dispenza,an international lecturer, researcher and author who has been invited to speak in more than 33 countries on six continents. Dr. Dispenza challenged the audience to rewire the brains and recondition their bodies to make lasting life changes.

Dr. Steven Greco, Chief Scientific Officer of the Houston Healthspan Innovation Group said, Regenerative medicine and immune restoration treatments provide safe, accessible options for patients. Houston Healthspan was pleased to share some of the exciting pilot data related to orthopedic and neurological treatments delivered at Okyanos. Through our participation and the sponsorship of the Bosarge Family Foundation, we were able to collaborate on this Summit because of our shared commitment to HEALinc., and to The Bahamas.

Dr. Joshua Hare, Professor of Medicine at University of Miami and Co-founder and Chief Scientific Officer of Longeveron, presented important scientific data from Longeverons multiple FDA authorized stem cell trials in the US as well as the 60+ patients treated in The Bahamas in Longeverons approved open Registry for aging and musculoskeletal related disorders.Dr. Todd McAllister, CEO of Fountain Therapeutics scheduled to begin operations in Bimini was a keynote speaker at the Summit along with Dr. Robert Hariri, Founder and President of Celularity, and one of the angel investors of Fountain Therapeutics along with Peter Diamandis and Tony Robbins. Dr. Hariri says, This Summit is an ideal environment to engage in conversations that affirm our commitment to harnessing the powerful biology of the placenta to treat cancer, immunological and degenerative diseases and we commend Dr. Cox for her leadership in this regard.

Dr. Cox says, As we grow, we anticipate hosting events in the United States that provide a space for more individuals to showcase products and services that will allow more persons to live longer, healthier and happier lives because of the integration of modern and ancient regenerative health technologies.

The rest is here:
Second annual Regenerative Medicine summit proves big win for The Bahamas - EyeWitness News

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Is Segmented On The Basis Of Product, Technology And End User 2026 – Statsflash

Global Platelet Rich Plasma & Stem Cell Alopecia Treatment Market- Snapshot

The global platelet rich plasma & stem cell alopecia treatment market is expected to reach a value of approximately US$ 450.5 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period. Factors such as increase in demand for accurate and prompt treatment of alopecia and advancements in platelet rich plasma and stem cell therapies that have revolutionized the diagnostic science are likely to boost the market.

View Report:https://www.transparencymarketresearch.com/platelet-rich-plasma-stem-cell-alopecia-treatment-market.html

Moreover, a rise in awareness about platelet rich plasma therapies and stem cell therapies is expected to drive the global market during the forecast period. Increased awareness has driven demand for platelet rich plasma therapy & stem cell therapy in the past few years in countries such as Japan, India, Brazil, and Russia and developed regions such as North America and Europe. Additionally, private players are actively promoting the advantages of treatment of alopecia with stem cell therapy across the globe. A rise in the incidence rates of autoimmune hair loss disorders such as alopecia is estimated to boost the platelet rich plasma & stem cell alopecia treatment market. According to the Journal of Clinical, Cosmetic, and Investigational Dermatology, 2015, the lifetime incidence rate of alopecia areata is approximately 2% worldwide. This is expected to propel the market. However, a lack of treatment approval and high cost of alopecia treatment are likely to hinder the growth of platelet rich plasma & stem cell alopecia treatment market.

The global platelet rich plasma & stem cell alopecia treatment market has been segmented based on treatment, indication, end-user, and region. In terms of treatment, the global market has been classified into platelet rich plasma therapies and stem cell therapy. The platelet rich plasma therapies segment held a major market share and is expected to expand at a significant CAGR, owing to the effectiveness of the therapies in the treatment of many types of alopecia. Platelet rich plasma therapies have revolutionized alopecia treatment by reducing costs, treatment duration, and recovery time for patients. The stem cell therapy segment has been further divided into bone marrow and adipose. Based on indication, the global platelet rich plasma & stem cell alopecia treatment market has been divided into androgenic alopecia, congenital alopecia, cicatricial or scarring alopecia, and others.

Request a Brochure of Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=55800

The androgenic alopecia segment holds a key market share as androgenic alopecia is the most common cause of hair loss in both men and women. About 45% men and 35% women develop androgenic alopecia by 60, which is the highest among all the types of alopecia. A study published in the International Journal of Womens Dermatology in 2019 revealed that the use of PRP to treat androgenic alopecia is promising due to its autologous nature, minimal invasiveness, lack of major side effects, and low cost compared to hair restoration surgery.

In terms of end-user, the global market has been categorized into hospitals, dermatology clinics, and others. The dermatology clinics segment held a major share of the market, followed by the hospital segment, in 2017. This is due to an increase in preference among patients for dermatology clinics where they can avail combined treatment for hair, skin, and nails. Moreover, an increase in incidence of alopecia, rise in access to dermatologists, and surge in awareness about services provided by dermatology clinics are factors attributable to the high market share of the segment. Certain hospitals have diagnostic facilities, including hair & scalp computerized analysis, in-house laboratory, and a number of different treatment options. This is likely to boost the global market, especially in developing regions.

In terms of region, the global platelet rich plasma & stem cell alopecia treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global platelet rich plasma & stem cell alopecia treatment market, owing to high rate of adoption of advanced products and rise in market penetration of new market entrants with novel technology in the region. Moreover, high prevalence of alopecia in the region is imposing a significant economic burden and is boosting demand for affordable care. This, in turn, is driving demand for platelet rich plasma & stem cell alopecia treatment. According to the National Institute of Health in 2015, 95% of women suffer from androgenetic alopecia in the U.S.. This has led the country to dominate the platelet rich plasma & stem cell alopecia treatment market in North America. The U.S. is anticipated to maintain its leading position in the market in the region during the forecast period. Additionally, increased application of PRP for the treatment of alopecia has been observed in the past few years. This is likely to fuel the market in the region. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to the emergence of strong local manufacturers offering various technological advancements for platelet rich plasma & stem cell alopecia treatment at lower prices and increase in awareness among people about these treatment methods. Furthermore, an increase in health care expenditure and investments by key players in emerging regions such as China and India are estimated to fuel the market in the region.

Request a Sample of Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=55800

Major players operating in the global platelet rich plasma & stem cell alopecia treatment market include Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy. Key players are focused on research & development of alopecia treatment by investing in platelet rich plasma & stem cell alopecia therapies. Mergers & acquisitions, collaborations, and partnerships are helping companies expand their footprint and further develop effective treatments for alopecia.

The rest is here:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Is Segmented On The Basis Of Product, Technology And End User 2026 - Statsflash